Latest information on talazoparib medical insurance in 2024

Talazoparib, as an oral polyADP ribose polymerase (PARP) inhibitor, plays a key role in the DNA damage repair process by inhibiting PARP enzyme activity, thereby effectively slowing the growth and spread of cancer cells. This drug has important implications for the treatment of patients with HER2-negative locally advanced or metastatic breast cancer who carry deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA) mutations. In 2023, the drug was also confirmed to be effective in adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer. However, the price of the original drug of talazoparib is relatively expensive, which prohibits many patients from using it. Therefore, its medical insurance issue has attracted much attention.

Regarding the latest information about talazoparib in the medical insurance field, the drug has not yet been officially included in China’s medical insurance directory. This results in that even though talazoparib has significant therapeutic effects and potential, patients still have to bear its relatively high cost. What is even more regrettable is that talazoparib has not yet been approved by the China Food and Drug Administration, so patients cannot purchase the drug directly in domestic pharmacies.

In the international market, Talazoparib produced by Pfizer provides two different specifications to meet the treatment needs of different patients. Among them, the price of the drug with the specification of 0.25mg*30 pills is about more than 18,000 yuan, while the price of the medicine with the specification of 1mg*30 pills is nearly 50,000 yuan.

For patients with limited financial conditions, purchasing generic drugs from overseas may be a relatively economical option. For example, the Laos element version of generic medicine is one option. Its specifications are 1mg*30 pills per box, and the price is about 4,000 yuan. However, it should be noted that drug selling prices may fluctuate slightly due to exchange rates.

It should be noted that there are certain risks in purchasing drugs overseas. Be sure to choose reputable and guaranteed formal channels to ensure the quality and safety of the drugs. At the same time, we look forward to talazoparib being approved in China and included in the medical insurance directory in the future, bringing treatment hope to more patients.